Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan

Antiviral Research

Volumn 99, Issue 3, 2013, Pages 261-269

  Dapat, Clyde ^a   Kondo, Hiroki ^a   Dapat, Isolde C ^a   Baranovich, Tatiana ^a,c   Suzuki, Yasushi ^a,d   Shobugawa, Yugo ^a   Saito, Kousuke ^a   Saito, Reiko ^a   Suzuki, Hiroshi ^b  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA SEIRYO UNIVERSITY   (Japan)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d NATIONAL INSTITUTE OF ANIMAL HEALTH   (Japan)

Author keywords

Half maximal inhibitory concentration (IC50); Influenza; Laninamivir; Oseltamivir; Peramivir; Zanamivir

Indexed keywords

LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; VIRUS SIALIDASE; ZANAMIVIR; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; NA PROTEIN, INFLUENZA A VIRUS; SIALIDASE; VIRUS PROTEIN; DRUG DERIVATIVE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHILD; CONTROLLED STUDY; ENZYME ASSAY; ENZYME INHIBITION; FEMALE; FLUORESCENCE ANALYSIS; HUMAN; HUMAN TISSUE; IC 50; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; JAPAN; MALE; NONHUMAN; NOSE SMEAR; NUCLEOTIDE SEQUENCE; PANDEMIC INFLUENZA; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SEASONAL INFLUENZA; THROAT CULTURE; VIRUS MUTATION; VIRUS STRAIN; ADULT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; PANDEMIC; SEASON; VIROLOGY; ADOLESCENT; ANTIVIRAL SUSCEPTIBILITY; GENE MUTATION; GENE SEQUENCE; HUMAN CELL; INFANT; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; RANDOMIZED CONTROLLED TRIAL; DRUG ANTAGONISM; DRUG EFFECT; HALF MAXIMAL INHIBITORY CONCENTRATION (IC50); INFLUENZA;

ADULT; ANTIVIRAL AGENTS; CYCLOPENTANES; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; FEMALE; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; JAPAN; MICROBIAL SENSITIVITY TESTS; NEURAMINIDASE; PANDEMICS; SEASONS; VIRAL PROTEINS; ZANAMIVIR;

HALF MAXIMAL INHIBITORY CONCENTRATION (IC50); INFLUENZA; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; ZANAMIVIR;

EID: 84884574122     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.06.003     Document Type: Article

References (46)

1. Baranovich T., Saito R., Suzuki Y., Zaraket H., Dapat C., Caperig Dapat I., Oguma T., Shabana I.I., Saito T., Suzuki H. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season. J. Clin. Virol. 2010, 47:23-28. J. I. C. S. Group.
2. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The protein data bank. Nucleic Acids Res. 2000, 28:235-242.
3. Besselaar T., Naidoo D., Buys A., Gregory V., McAnerney J., Manamela J., Blumberg L., Schoub B. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg. Infect. Dis. 2008, 14:1809-1810.
4. Chen H., Cheung C.L., Tai H., Zhao P., Chan J.F., Cheng V.C., Chan K.H., Yuen K.Y. Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China. Emerg. Infect. Dis. 2009, 15:1970-1972.
5. Colman P.M. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci. 1994, 3:1687-1696.
6. Colman P.M., Hoyne P.A., Lawrence M.C. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J. Virol. 1993, 67:2972-2980.
7. Dapat C., Saito R., Kyaw Y., Naito M., Hasegawa G., Suzuki Y., Dapat I., Zaraket H., Cho T., Li D., Oguma T., Baranovich T., Suzuki H. Epidemiology of human influenza A and B viruses in Myanmar from 2005 to 2007. Intervirology 2009, 52:310-320.
8. Dapat I.C., Dapat C., Baranovich T., Suzuki Y., Kondo H., Shobugawa Y., Saito R., Suzuki H. Genetic characterization of human influenza viruses in the pandemic (2009-2010) and post-pandemic (2010-2011) periods in Japan. PLoS One 2012, 7:e36455. J.I.C.S. Group.
9. Dharan N., Gubareva L., Meyer J., Okomo-Adhiambo M., McClinton R., Marshall S., St George K., Epperson S., Brammer L., Klimov A., Bresee J., Fry A. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009, 301:1034-1041.
10. Gubareva L.V. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 2004, 103:199-203.
11. Hauge S., Dudman S., Borgen K., Lackenby A., Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg. Infect. Dis. 2009, 15:155-162.
12. Hurt A., Barr I., Hartel G., Hampson A. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res. 2004, 62:37-45.
13. Hurt A., Ernest J., Deng Y., Iannello P., Besselaar T., Birch C., Buchy P., Chittaganpitch M., Chiu S., Dwyer D., Guigon A., Harrower B., Kei I., Kok T., Lin C., McPhie K., Mohd A., Olveda R., Panayotou T., Rawlinson W., Scott L., Smith D., D'Souza H., Komadina N., Shaw R., Kelso A., Barr I. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 2009, 83:90-93.
14. Hurt A.C., Deng Y.M., Ernest J., Caldwell N., Leang L., Iannello P., Komadina N., Shaw R., Smith D., Dwyer D.E., Tramontana A.R., Lin R.T., Freeman K., Kelso A., Barr I.G. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010. Euro. Surveill. 2011, 16.
15. Hurt A.C., Hardie K., Wilson N.J., Deng Y.M., Osbourn M., Gehrig N., Kelso A. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N. Engl. J. Med. 2011, 365:2541-2542.
16. Hurt A.C., Lee R.T., Leang S.K., Cui L., Deng Y.M., Phuah S.P., Caldwell N., Freeman K., Komadina N., Smith D., Speers D., Kelso A., Lin R.T., Maurer-Stroh S., Barr I.G. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro. Surveill. 2011, 16.
17. Hurt A.C., Hardie K., Wilson N.J., Deng Y.M., Osbourn M., Leang S.K., Lee R.T., Iannello P., Gehrig N., Shaw R., Wark P., Caldwell N., Givney R.C., Xue L., Maurer-Stroh S., Dwyer D.E., Wang B., Smith D.W., Levy A., Booy R., Dixit R., Merritt T., Kelso A., Dalton C., Durrheim D., Barr I.G. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J. Infect. Dis. 2012, 206:148-157.
18. Infectious_Disease_Surveillance_Center (2012). Flash Report on Influenza Virus in Japan: City.
19. Inoue M., Barkham T., Leo Y.S., Chan K.P., Chow A., Wong C.W., Lee Tze Chuen, Maurer-Stroh R., Lin S., Lin C. Emergence of oseltamivir-resistant pandemic (H1N1) 2009 virus within 48 hours. Emerg. Infect. Dis. 2010, 16:1633-1636.
20. Kohno S., Kida H., Mizuguchi M., Shimada J. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob. Agents Chemother. 2010, 54:4568-4574. S.-C. S. Group.
21. Le Q.M., Wertheim H.F., Tran N.D., van Doorn H.R., Nguyen T.H., Horby P. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N. Engl. J. Med. 2010, 362:86-87. V.H.N.I. Team.
22. Lin Y.P., Gregory V., Collins P., Kloess J., Wharton S., Cattle N., Lackenby A., Daniels R., Hay A. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?. J. Virol. 2010, 84:6769-6781.
23. Longtin J., Patel S., Eshaghi A., Lombos E., Higgins R., Alexander D., Olsha R., Doyle J., Tran D., Sarabia A., Lee C., Bastien N., Li Y., Low D., Boivin G., Gubbay J. Neuraminidase-inhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada. J. Clin. Virol. 2011, 50:257-261.
24. McKimm-Breschkin J., Trivedi T., Hampson A., Hay A., Klimov A., Tashiro M., Hayden F., Zambon M. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 2003, 47:2264-2272.
25. Monto A., McKimm-Breschkin J., Macken C., Hampson A., Hay A., Klimov A., Tashiro M., Webster R., Aymard M., Hayden F., Zambon M. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 2006, 50:2395-2402.
26. Moore C., Galiano M., Lackenby A., Abdelrahman T., Barnes R., Evans M.R., Fegan C., Froude S., Hastings M., Knapper S., Litt E., Price N., Salmon R., Temple M., Davies E. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. J. Infect. Dis. 2011, 203:18-24.
27. Moscona A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 2005, 353:1363-1373.
28. Mungall B.A., Xu X., Klimov A. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons. Virus Res. 2004, 103:195-197.
29. Nguyen H.T., Fry A.M., Loveless P.A., Klimov A.I., Gubareva L.V. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin. Infect. Dis. 2010, 51:983-984.
30. Nguyen H.T., Sheu T.G., Mishin V.P., Klimov A.I., Gubareva L.V. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob. Agents Chemother. 2010, 54:3671-3677.
31. Okomo-Adhiambo M., Nguyen H., Sleeman K., Sheu T., Deyde V., Garten R., Xu X., Shaw M., Klimov A., Gubareva L. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res. 2010, 85:381-388.
32. Okomo-Adhiambo M., Sleeman K., Ballenger K., Nguyen H.T., Mishin V.P., Sheu T.G., Smagala J., Li Y., Klimov A.I., Gubareva L.V. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses 2010, 2:2269-2289.
33. Okomo-Adhiambo M., Sheu T.G., Gubareva L.V. Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors. Influenza Other Respir. Viruses 2013, 7(Suppl. 1):44-49.
34. Pozo F., Lina B., Andrade H.R., Enouf V., Kossyvakis A., Broberg E., Daniels R., Lackenby A., Meijer A. Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe. J. Clin. Virol. 2013.
35. Puzelli S., Facchini M., Di Martino A., Fabiani C., Lackenby A., Zambon M., Donatelli I. Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic. Antiviral Res. 2011, 90:205-212.
36. Sheu T.G., Deyde V.M., Okomo-Adhiambo M., Garten R.J., Xu X., Bright R.A., Butler E.N., Wallis T.R., Klimov A.I., Gubareva L.V. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 2008, 52:3284-3292.
37. Sugaya N. Widespread use of neuraminidase inhibitors in Japan. J. Infect. Chemother. 2011, 17:595-601.
38. Sy C.L., Lee S.S., Liu M.T., Tsai H.C., Chen Y.S. Rapid emergence of oseltamivir resistance. Emerg. Infect. Dis. 2010, 16:723-725.
39. Tashiro M., McKimm-Breschkin J., Saito T., Klimov A., Macken C., Zambon M., Hayden F. Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007. Antivir. Ther. 2009, 14:751-761.
40. Ujike M., Shimabukuro K., Mochizuki K., Obuchi M., Kageyama T., Shirakura M., Kishida N., Yamashita K., Horikawa H., Kato Y., Fujita N., Tashiro M., Odagiri T. Oseltamivir-resistant influenza viruses A (H1N1) during 2007-2009 influenza seasons, Japan. Emerg. Infect. Dis. 2010, 16:926-935. Japan W.G.f.I.V.S.i.
41. Ujike M., Ejima M., Anraku A., Shimabukuro K., Obuchi M., Kishida N., Hong X., Takashita E., Fujisaki S., Yamashita K., Horikawa H., Kato Y., Oguchi A., Fujita N., Tashiro M., Odagiri T. Monitoring and characterization of Oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010. Emerg. Infect. Dis. 2011, 17:470-479. Japan a.t.I.V.S.G.o.
42. van der Vries E., Stelma F.F., Boucher C.A. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N. Engl. J. Med. 2010, 363:1381-1382.
43. van der Vries E., Veldhuis Kroeze E.J., Stittelaar K.J., Linster M., Van der Linden A., Schrauwen E.J., Leijten L.M., van Amerongen G., Schutten M., Kuiken T., Osterhaus A.D., Fouchier R.A., Boucher C.A., Herfst S. Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets. PLoS Pathog. 2011, 7:e1002276.
44. Vavricka C.J., Li Q., Wu Y., Qi J., Wang M., Liu Y., Gao F., Liu J., Feng E., He J., Wang J., Liu H., Jiang H., Gao G.F. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. PLoS Pathog. 2011, 7:e1002249.
45. WHO_Global_Influenza_Surveillance_Network (2011). Manual for the laboratory diagnosis and virological surveillance of influenza: City. World_Health_Organization (2012). Meetings of the WHO working group on surveillance of influenza antiviral susceptibility - Geneva, November 2011 and June 2012: City, pp. 369-374.
46. Yamashita M., Tomozawa T., Kakuta M., Tokumitsu A., Nasu H., Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob. Agents Chemother. 2009, 53:186-192.